Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Consensus PT from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen analysts that are currently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $30.56.

A number of research analysts recently issued reports on the stock. HC Wainwright decreased their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Scotiabank decreased their price target on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a report on Monday, May 12th. Truist Financial dropped their price objective on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Wedbush restated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. Finally, Bank of America cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the company from $32.00 to $18.00 in a report on Tuesday, June 10th.

Keros Therapeutics Price Performance

Shares of KROS stock remained flat at $14.32 on Thursday. The company had a trading volume of 261,048 shares, compared to its average volume of 448,280. The firm has a 50-day moving average of $14.06 and a 200 day moving average of $12.66. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $72.37. The firm has a market capitalization of $581.68 million, a price-to-earnings ratio of -79.56, a P/E/G ratio of 2.59 and a beta of 1.33.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The business had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a net margin of 1.96% and a return on equity of 0.75%. During the same quarter in the previous year, the firm posted ($1.21) earnings per share. Equities analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of KROS. GAMMA Investing LLC increased its stake in Keros Therapeutics by 7,690.3% in the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock valued at $237,000 after purchasing an additional 2,384 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in Keros Therapeutics during the 1st quarter valued at $25,000. CWM LLC increased its position in Keros Therapeutics by 10,157.7% during the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after buying an additional 2,641 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Keros Therapeutics during the fourth quarter valued at $90,000. Institutional investors and hedge funds own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.